Targets › FGFR1
36 programs from 32 companies in 162 trials: 108 Phase 2, 38 Phase 1, 15 Phase 3, 1 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal…. (UniProt, P11362)
Open in Phaseline: the race on FGFR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TransThera Sciences (Nanjing) | TT-00420 (tinengotinib) Fibroblast growth factor receptor (FGFR) inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 3 | Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC) | Dec 2026 |
| Exelixis | Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| Xynomic Pharmaceuticals | Pazopanib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory … | Dec 2026 |
| Johnson & Johnson (Janssen) | Erdafitinib (TAR-210) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 3 | Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm … | Dec 2026 |
| National Cancer Institute (NCI) | Pazopanib Hydrochloride Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid Neoplasm | Feb 2027 |
| Taiho Oncology | Futibatinib (TAS-120) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms … | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Gastrointestinal Cancer | Dec 2026 |
| Fei Gao | Donafenib Multi-kinase inhibitor targeting FGFR and VEGFR | FGFR1, VEGFR1, VEGFR2, VEGFR3 | Phase 2 | Hepatocellular Carcinoma with PVTT | Dec 2026 |
| Shanghai Zhongshan Hospital | HRS-4642 FGFR1/2/3/4 inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Biliary Tract Cancer; Pancreatic Cancer | Dec 2026 |
| Sameek Roychowdhury | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Advanced Pancreatic Carcinoma | Dec 2026 |
| University of Utah | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Mar 2027 |
| Shanghai Zhongshan Hospital | HEC88473 GLP-1/FGF21 dual agonist | GLP1R, FGFR1 | Phase 2 | PCOS (Polycystic Ovary Syndrome) | Jun 2027 |
| UNICANCER | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Solid Tumor, Miscellaneous | Jun 2027 |
| Mehmet Akce | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Intrahepatic Cholangiocarcinoma | Jul 2027 |
| National Cancer Institute (NCI) | Rogaratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Locally Advanced Gastrointestinal Stromal Tumor | Jul 2027 |
| Ohio State University Comprehensive Cancer Center | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Locally Advanced Ampulla of Vater Carcinoma | Dec 2027 |
| Haitao Zhao, MD | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Biliary Tract Cancer (BTC) | Dec 2027 |
| Lund University Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | Dedifferentiated Liposarcoma | Dec 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Donafenib Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Hepatocellular Carcinoma | Jan 2028 |
| National Cancer Center, Japan | E7090 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Advanced or Recurrent Solid Tumors | Mar 2028 |
| Bayer | Regorafenib (BAY73) Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor | ABL1, RAF1, KIT, FGFR1, MAPK11 | Phase 2 | Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic … | Apr 2028 |
| Hutchmed | Surufatinib Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | FGFR1, FLT1, FLT4, KDR | Phase 2 | Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma … | May 2028 |
| Hutchmed | Hmpl-453 (HMPL-453) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 2 | Advanced Intrahepatic Cholangiocarcinoma | Jun 2028 |
| Dana-Farber Cancer Institute | Pemigatinib (INCB054828) Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 2 | SDH Gene Mutation | Oct 2028 |
| QED Therapeutics, a BridgeBio company | Infigratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Achondroplasia | Mar 2030 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Derazantinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Intrahepatic Cholangiocarcinoma | – |
| Biohaven Therapeutics | Taldefgrobep Alfa FGF21 receptor agonist (FGF21 analog) | FGFR1, FGFR4, KLB | Phase 2 | Obesity | – |
| AstraZeneca | Fexagratinib (AZD4547) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 1 | Muscle Invasive Bladder Cancer; Metastatic Breast Cancer | Nov 2026 |
| OHSU Knight Cancer Institute | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| Kidney Cancer Research Bureau | OM-RCA-01 humanized monoclonal anti-FGFR1 antibody | FGFR1 | Phase 1 | Renal Cell Carcinoma Metastatic | Jan 2027 |
| Tyra Biosciences | TYRA-200 FGFR 1/2/3 tyrosine kinase inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Locally Advanced Cholangiocarcinoma | Mar 2027 |
| Eisai | E-7090 (E7090) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 1 | Hepatic Impairment | Aug 2027 |
| Massachusetts General Hospital | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Tyra Biosciences | TYRA-430 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 1 | Metastatic Hepatocellular Carcinoma | Jan 2028 |
| M.D. Anderson Cancer Center | Pemigatinib Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor | FGFR2, FGFR3, FGFR1 | Phase 1 | Advanced Cholangiocarcinoma | Feb 2028 |
| Roche | GDC-4198 FGFR1 inhibitor | FGFR1 | Phase 1 | Breast Cancer | Aug 2028 |
Hepatocellular Carcinoma (5) Colorectal Cancer (5) Non-Muscle Invasive Bladder Neoplasms (3) Intrahepatic Cholangiocarcinoma (3) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Advanced Cholangiocarcinoma (2) Advanced Solid Tumor (2) Pancreatic Cancer (2) Hepatic Impairment (2) Breast Cancer (2) Colorectal Cancer Metastatic (2)
small molecule (23), mixed (10), antibody (2), protein or peptide (1)
Shanghai Zhongshan Hospital (2) Tyra Biosciences (2) National Cancer Institute (NCI) (2) Hutchmed (2) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Johnson & Johnson (Janssen) (1) Taiho Oncology (1) Massachusetts General Hospital (1) Exelixis (1) UNICANCER (1) Kidney Cancer Research Bureau (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) TransThera Sciences (Nanjing) (1) Mehmet Akce (1) Bayer (1) University of Utah (1) Tianjin Medical University Cancer Institute and Hospital (1) Fei Gao (1)
FGFR3 (29) FGFR2 (27) FGFR4 (13) KIT (4) CSF1R (2) LCK (2) MET (1) PDGFRA (1) ABL1 (1) RAF1 (1) MAPK11 (1) GLP1R (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.